Align Technology (ALGN) traded sharply lower, down roughly 6% to about $166, after a recent bounce tied to news that activist Elliott Investment Management had built a major stake. With no new company update driving the move, traders appeared to be fading the prior catalyst and reducing exposure into a volatile tape for discretionary healthcare names. †cite turn3search4 

The most immediate driver looks like profit-taking following the Elliott-stake headline, which had lifted shares and increased near-term positioning. As the initial excitement cools, the market is refocusing on core fundamentals—case starts, consumer affordability, and the pace of recovery in orthodontic demand—areas that have recently made the stock highly reactive to sentiment shifts. †cite turn3search4 

Investors are watching for any follow-through on Elliott’s involvement (board engagement, strategic priorities, capital return, or margin initiatives) and for incremental demand signals from conferences, channel checks, or future quarterly updates. Separately, recurring investor-law-firm investigation headlines remain a sentiment overhang that can amplify downside on weak days even when not tied to new disclosures. †cite turn1search0  †cite turn1search2